PTS, Inc. (PTSH) New Study Show Promising Effects of Cinnamon in the Treatment of Alzheimer’s Disease
A new study suggests that cinnamon may help delay the onset or ward off the effect of Alzheimer’s disease. The study entitled Interaction of Cinnamaldehyde and Epicatechin with Tau: Implications of Beneficial Effects in Modulating Alzheimer's Disease Pathogenesis has been published in the online early edition of the Journal Of Alzheimer’s Disease, Volume 36 Issue 1. Roshni Georges and Donald Graves, scientists at University of California, Santa Barbara`have identified 2 compounds found in cinnamon- Cinnamaldehyde and Epicatechin- both which show promise in fighting the disease. According to the study, these compounds have been shown to prevent the development of filamentous ‘tangles’ that are found in the brain cells that characterize Alzheimer’s disease.
A protein in the brain called Tau has been identified as playing a large role in the onset of the disease. When this protein does not bind properly to microtubules that form the cell’s structure, insoluble fibres can form in the neuron’s. The use of cinnamaldehyde, the compound responsible for the bright, sweet smell of cinnamon, has proven effective in preventing the tau knots. By protecting tau from oxidative stress, the compound, an oil, could inhibit the protein's aggregation. To do this, cinnamaldehyde binds to two residues of an amino acid called cysteine on the tau protein. The cysteine residues are vulnerable to modifications, a factor that contributes to the development of Alzheimer's. Further information can be obtained at http://www.cingx.com/can-cinnamon-prevent-alzheimer-s-disease/
Michael Arnkvarn, CEO states, ``We have known that our CinG-X product could help with dementia and Alzheimer’s disease through our own research. It is very exciting to see additional scientific evidence to support our affirmations. This research will help educate our aging population on the multiple benefits of taking CinG-X on a daily basis’
In other news, the company is continuing its filings and has become OTC current and will continue to keep its shareholders and followers informed on a timely basis.
Safe Harbor Statement
Information in this release may contain statements about future expectations, plans, prospects or performance of PTS Inc. (PTSH) that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. PTS Inc. (PTSH) cautions you that any forward-looking information provided by or on behalf of PTS Inc. (PTSH) is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. PTS Inc. (PTSH)'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond PTS Inc. (PTSH)'s control. In addition to those discussed in PTS Inc. (PTSH)'s press releases, public filings, and statements by PTS Inc. (PTSH)'s management, including, but not limited to, PTS Inc. (PTSH)'s estimate of the sufficiency of its existing capital resources, PTS Inc. (PTSH)'s ability to raise additional capital to fund future operations, PTS Inc. (PTSH)'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match PTS Inc. (PTSH)'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. PTS Inc. (PTSH) does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
- Disease & Medical Conditions